ReviewSeminars in thrombosis and hemostasis2007
Enzymatic synthesis of glycosaminoglycan heparin.
Review in Seminars in thrombosis and hemostasis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Small tools for sweet challenges: advances in microfluidic technologies for glycan synthesis.Analytical and bioanalytical chemistry · 2022Review
- The Choice of Anticoagulant Influences the Characteristics of Bone Marrow Aspirate Concentrate and Mesenchymal Stem Cell Bioactivity In Vitro.Stem cells international · 2022Article
- Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.Thrombosis journal · 2021Review
- Chemical Modification of Glycosaminoglycan Polysaccharides.Molecules (Basel, Switzerland) · 2021Review
- Developments in Mass Spectrometry for Glycosaminoglycan Analysis: A Review.Molecular & cellular proteomics : MCP · 2021Review
- Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.Antiviral research · 2020Article
- Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides.Chemical communications (Cambridge, England) · 2018Article
- Divergent Synthesis of Heparan Sulfate Oligosaccharides.The Journal of organic chemistry · 2015Article
- Fluorous supported modular synthesis of heparan sulfate oligosaccharides.Organic letters · 2013Article
- Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin.Metabolic engineering · 2012Article
- Harnessing glycomics technologies: integrating structure with function for glycan characterization.Electrophoresis · 2012Review
- Ozonolysis of the double bond of the unsaturated uronate residue in low-molecular-weight heparin and K5 heparosan.Carbohydrate research · 2011Article
- Preactivation-based, one-pot combinatorial synthesis of heparin-like hexasaccharides for the analysis of heparin-protein interactions.Chemistry (Weinheim an der Bergstrasse, Germany) · 2010Article
- Generating heparan sulfate saccharide libraries for glycomics applications.Nature protocols · 2010Article
- Glycosaminoglycans from earthworms (Eisenia andrei).Glycoconjugate journal · 2010Article
- Polysaccharide-modified synthetic polymeric biomaterials.Biopolymers · 2010Review
- Modular synthesis of heparan sulfate oligosaccharides for structure-activity relationship studies.Journal of the American Chemical Society · 2009Article
- Quantification of heparan sulfate disaccharides using ion-pairing reversed-phase microflow high-performance liquid chromatography with electrospray ionization trap mass spectrometry.Analytical chemistry · 2009Article
- Lessons learned from the contamination of heparin.Natural product reports · 2009Review
- Synthesis of uridine 5'-diphosphoiduronic acid: a potential substrate for the chemoenzymatic synthesis of heparin.The Journal of organic chemistry · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Heparin and its low molecular weight heparin derivatives, widely used as clinical anticoagulants, are acidic polysaccharide members of a family of biomacromolecules called glycosaminoglycans (GAGs). Heparin and the related heparan sulfate are biosynthesized in the Golgi apparatus of eukaryotic cells. Heparin is a polycomponent drug that currently is prepared for clinical use by extraction from animal tissues. A heparin pentasaccharide, fondaparinux, has also been prepared through chemical synthesis for use as a homogenous anticoagulant drug. Recent enabling technologies suggest that it may now be possible to synthesize heparin and its derivatives enzymatically. Moreover, new technologies including advances in synthetic carbohydrate synthesis, enzyme-based GAG synthesis, micro- and nano-display of GAGs, rapid on-line structural analysis, and microarray/microfluidic technologies might be applied to the enzymatic synthesis of heparins with defined structures and exhibiting selected activities. The advent of these new technologies also makes it possible to consider the construction of an artificial Golgi to increase our understanding of the cellular control of GAG biosyntheses in this organelle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.